We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-3.89%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.3B
AUM Growth
-$140M
Cap. Flow
+$106M
Cap. Flow %
4.61%
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$37.7M
2
DXCM icon
DexCom
DXCM
+$37.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$34.7M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$33.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$31.7M

Top Sells

Rank Stock Value
1
ONEM
1Life Healthcare
ONEM
+$38.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$38.2M
3
PLRX icon
Pliant Therapeutics
PLRX
+$27.1M
4
AKRO
Akero Therapeutics
AKRO
+$26.2M
5
REPL icon
Replimune Group
REPL
+$24.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.91%
2 Industrials 1.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
51
DELISTED
RAPT Therapeutics
RAPT
$12.6M 0.55%
86,017
-12,087
-12% -$2.44M
ALLK
52
DELISTED
Allakos
ALLK
$10.2M 0.44%
2,286,177
-259,098
-10% -$1.66M
MDVL
53
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$9.92M 0.43%
692,090
– –
BSX icon
54
Boston Scientific
BSX
$67.9B
$8.59M 0.37%
+171,780
New +$8.1M
ILMN icon
55
Illumina
ILMN
$32.6B
$7.79M 0.34%
+34,434
New +$7.05M
KLRS
56
Kalaris Therapeutics
KLRS
$95.9M
$7.52M 0.33%
82,955
– –
SNCE
57
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$5.58M 0.24%
990,412
– –
GRFS
58
Grifois
GRFS
$5.23B
$5.31M 0.23%
720,784
+395,184
+121% +$3.43M
NUVB icon
59
Nuvation Bio
NUVB
$2.34B
$5.03M 0.22%
3,031,009
– –
SLGC
60
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.77M 0.21%
1,870,839
+370,839
+25% +$1.06M
LVTX
61
DELISTED
LAVA Therapeutics
LVTX
$3.44M 0.15%
2,074,372
-741,824
-26% -$2.08M
NVTA
62
DELISTED
Invitae Corporation
NVTA
$3.08M 0.13%
2,280,403
– –
STXS icon
63
Stereotaxis
STXS
$145M
$3.03M 0.13%
1,487,495
– –
ALXO icon
64
ALX Oncology
ALXO
$277M
$2.65M 0.12%
586,977
-20,493
-3% -$155K
CABA icon
65
Cabaletta Bio
CABA
$529M
$2.27M 0.1%
274,252
-190,000
-41% -$1.78M
HOOK
66
DELISTED
HOOKIPA Pharma
HOOK
$1.88M 0.08%
255,295
-56,182
-18% -$503K
IVVD icon
67
Invivyd
IVVD
$284M
$1.73M 0.08%
1,440,725
– –
XERS icon
68
Xeris Biopharma Holdings
XERS
$1.55B
$1.71M 0.07%
1,046,587
– –
ACHL
69
DELISTED
Achilles Therapeutics
ACHL
$1.54M 0.07%
1,608,089
– –
NGNE icon
70
Neurogene
NGNE
$732M
$1.29M 0.06%
92,380
-148
-0.2% -$1.74K
TKNO icon
71
Alpha Teknova
TKNO
$382M
$1.1M 0.05%
373,244
-184,855
-33% -$924K
SONX
72
DELISTED
Sonendo, Inc.
SONX
$996K 0.04%
498,131
– –
TCRR
73
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$988K 0.04%
658,336
-73,043
-10% -$98.4K
CTSO icon
74
Cytosorbents Corp
CTSO
$21.1M
$612K 0.03%
181,639
-84,726
-32% -$254K
BCEL
75
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$505K 0.02%
442,653
– –
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2023 Portfolio in Review

As of Q1 2023, Redmile Group held 80 positions worth $2.3B, down 5.7% from $2.44B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $106M of net new capital in Q1 2023, opening 11 new positions and adding to 12 existing holdings. Its largest new stake was CATALENT, INC.: 610,304 shares worth $40.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $38.2M trimmed.

  • Redmile Group's largest Q1 2023 buy was CATALENT, INC.: 610,304 shares worth $40.1M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2023, an estimated $33.2M increase.
  • Redmile Group's biggest Q1 2023 reduction was Xenon Pharmaceuticals, cutting an estimated $38.2M.
  • Redmile Group fully exited 1Life Healthcare in Q1 2023, selling an estimated $38.9M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q1 2023.
  • Redmile Group opened 11 new positions and closed 4 in Q1 2023.
  • Redmile Group's portfolio value fell 5.7% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q1 2023, filed 15 May 2023.